In April of 2019, Kite, a Gilead Company, announced their decision to locate to Frederick County, MD and open a new manufacturing facility on a 20-acre site located at the Urbana Corporate Center. A lot of progress has happened since then; Kite finished their brand new 279,000 SF biologics manufacturing facility in April 2021. To learn more, Solash Aviles and Jodie Bollinger from the Frederick County Office of Economic Development met with Chris McDonald, Senior Vice President, Global Head of Manufacturing at Kite and Jim Jackson, Vice President, Manufacturing Operations and Site Head at Kite.
Congressman David Trone (MD-06) and Deputy Secretary of Commerce Don Graves toured Kite Pharma with the Maryland Tech Council on Friday.
BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD
BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the two companies have entered into a purchase agreement for BioNTech to acquire Kite’s solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD. The acquired Gaithersburg facility will provide production capacity to support clinical trials in the United States and will complement BioNTech’s existing cell therapy manufacturing facility in Idar-Oberstein, Germany. The facility will support the development of BioNTech’s expanding pipeline of novel cell therapies, including cancer product candidates based on its CAR-T Cell amplifying mRNA vaccine (CARVac) and NEOSTIM platforms as well as the newly acquired individualized neoantigen TCR program.
The BioHealth Capital Region (BHCR) has been witnessing a strong upward growth trajectory in recent years. The COVID-19 pandemic has only heightened the need for increased research, diagnostic and domestic manufacturing needs in the region. But while workforce needs are in demand, the right skills are in short supply.
Hood College to Partner with Kite Pharma to Train Employees for a New Facility in Urbana Hood College plans to partner with a pharmaceutical company to train employees for a [….]
At BioBuzz, we’ve written extensively about the promise of cell and gene therapeutics for both patients and the companies developing these revolutionary personalized medicines.
2020 was a year like no other for BioHealth Capital Region (BCHR) biotechs, and this year is expected to bring substantial growth across many sectors.
2020 found the United States embroiled in a chaotic political environment, reckoning with social unrest and racial injustice, and voting in one of the most consequential presidential elections in the country’s history.
Today, we are excited to announce the winners of our inaugural BioBuzz Awards. The BioBuzz Awards are a celebration of the exciting and groundbreaking work being done by the BioHealth Capital Region (BHCR) life science community and the individuals that make innovation happen across Maryland, Virginia, and Washington, D.C.
This year, more than ever before, we’ve seen just how important it is for us all to stay connected and work together to build a stronger biotech ecosystem. In the face of great adversity, the biotech community has risen to the challenge and formed new collaborations and partnerships to innovate and rapidly develop new medicines and tools to help us beat this pandemic.